Home >> Tag Archives: Celgene Corp.—

Tag Archives: Celgene Corp.—

Celgene acquires Juno Therapeutics, 4/18

April 2018—GlobalData says Celgene’s acquisition of Juno Therapeutics in January, for $9 billion, has put the company in a “good position to be a frontrunner in the chimeric antigen receptor-T cell space.” Celgene stands to benefit from Juno’s expertise and ongoing work in addressing concerns surrounding CAR-T, according to a release from GlobalData, a market research consulting company.

Read More »

Targeted AML drug Idhfa gets FDA OK

Aug. 3, 2017—Celgene and Agios Pharmaceuticals announced FDA approval of Idhfa (enasidenib) for the treatment of adult patients with relapsed or refractory AML with an isocitrate dehydrogenase-2 mutation as detected by an FDA-approved test. Idhfa, an oral targeted inhibitor of the IDH2 enzyme, is the first FDA-approved therapy for patients with relapsed or refractory AML and an IDH2 mutation, according ...

Read More »